Challenged claims of Dexcom Inc.'s patent that relates to systems and methods for transcutaneous measurement of glucose in a host are unpatentable as obvious over prior art, the Patent Trial and Appeal Board said, in an inter partes review by Abbott Diabetes Care Inc. The board said that the
the challenged claims are obvious over prior art that discloses analyte monitoring device and methods of use, a wearable sensor device and system, and a device and method of calibrating and testing a sensor for in vivo measurement of an analyte.
This story was produced by Bloomberg Law Automation.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.